{
  "claim_id": "claim_000",
  "claim": "Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
  "document": {
    "pdf_name": "Arunachalam_et_al.__2021_"
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 2
  },
  "extracted_evidence": [
    {
      "id": "comp_1",
      "quote": "The use of recombinant protein technology eliminates the risk of antigenic mismatch due to potential changes in primary HA structure through egg- or cell adaptation.",
      "relevance_explanation": "This quote directly supports the claim by stating that recombinant technology, as used in Flublok, eliminates the risk of antigenic mismatch that can occur with traditional egg- or cell-based vaccine production.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "Contrary to the egg derived vaccines and as expected, rHA containing the new glycosylation site induced optimal levels of antibodies that efficiently recognised the glycosylated clade 3 C.2 a H3 N2 virus 26.",
      "relevance_explanation": "This quote provides evidence that recombinant HA (as in Flublok) preserves the antigenic features of the selected strain, ensuring an identical match to the WHO- and FDA-selected strains, unlike egg-derived vaccines which may lose such features.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ]
}